title: Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
abstract: OBJECTIVE
  Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglitazone for preventing in-stent restenosis in type 2 diabetic patients.
  
  
  METHODS
  We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA.
  
  
  RESULTS
  Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosiglitazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 +/- 1.98 to 0.62 +/- 0.44 mg/l, P < 0.001 vs. from 2.01 +/- 1.33 to 1.79 +/- 1.22 mg/l, P = NS). However, the baseline and follow-up glucose and lipid concentrations were not different between two groups. The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2%, P = 0.030). The rosiglitazone group had a significantly lower degree of diameter stenosis (23.0 +/- 23.4% vs. 40.9 +/- 31.9%, P = 0.004) compared with the control group.
  
  
  CONCLUSIONS
  We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation.
authors.affiliation: Department of Internal Medicine, Yonsei University College of Medicine, 134 Shinchon-Dong, Seodaemoon-Ku, Seoul 120-749, Korea. bscha@yumc.yonsei.ac.kr.
authors.forename: Donghoon
authors.initials: D
authors.lastname: Choi
authors.forename: Soo-Kyung
authors.initials: SK
authors.lastname: Kim
authors.forename: Sung-Hee
authors.initials: SH
authors.lastname: Choi
authors.forename: Young-Guk
authors.initials: YG
authors.lastname: Ko
authors.forename: Chul-Woo
authors.initials: CW
authors.lastname: Ahn
authors.forename: Yangsoo
authors.initials: Y
authors.lastname: Jang
authors.forename: Sung-Kil
authors.initials: SK
authors.lastname: Lim
authors.forename: Hyun-Chul
authors.initials: HC
authors.lastname: Lee
authors.forename: Bong-Soo
authors.initials: BS
authors.lastname: Cha
mesh_terms: D000328:Adult; D000368:Aged; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000188:drug therapy / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003925:Diabetic Angiopathies / Q000188:drug therapy / Q000209:etiology / Q000628:therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D000077154:Rosiglitazone; D015607:Stents; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone